Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T21:36:57.387Z.
Calculation as of: 2026-10-06T21:36:57.387Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5aadd97284981d173c87413c67de95801d58f7ce8cc73935cbfc70b12a62615a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Generate Biomedicines, Inc.
Market Cap
$1.77B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.75B
Price/FCF Ratio
9.35
TTM Avg
10.13
3Y Avg
16.69
5Y Avg
44.23
Market Cap
$1.74B
Price/FCF Ratio
31.39
TTM Avg
64.78
3Y Avg
64.78
5Y Avg
64.78
Market Cap
$1.74B
Price/FCF Ratio
N/A
TTM Avg
131.77
3Y Avg
73.06
5Y Avg
73.06
Market Cap
$1.81B
Price/FCF Ratio
24.47
TTM Avg
31.22
3Y Avg
46.66
5Y Avg
45.78
Market Cap
$1.73B
Price/FCF Ratio
N/A
TTM Avg
13.58
3Y Avg
13.58
5Y Avg
13.58
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Generate Biomedicines, Inc. (GENB) | $1.77B | N/A | N/A | N/A | N/A |
| Surgery Partners, Inc. (SGRY)vs › | $1.75B | 9.35 | 10.13 | 16.69 | 44.23 |
| Novocure Ltd (NVCR)vs › | $1.74B | N/A | 414.74 | 302.73 | 386.97 |
| Absci Corporation (ABSI)vs › | $1.74B | N/A | N/A | N/A | N/A |
| Xeris Biopharma Holdings, Inc. (XERS)vs › | $1.74B | 31.39 | 64.78 | 64.78 | 64.78 |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.74B | N/A | 131.77 | 73.06 | 73.06 |
| Xencor, Inc. (XNCR)vs › | $1.81B | N/A | 228.23 | 155.55 | 119.73 |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.81B | 24.47 | 31.22 | 46.66 | 45.78 |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.73B | N/A | 13.58 | 13.58 | 13.58 |
| Azenta, Inc. (AZTA)vs › | $1.81B | 183.56 | 56.48 | 95.26 | 92.20 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute